JP2004523517A - 腫瘍増殖および転移を調節するための方法 - Google Patents

腫瘍増殖および転移を調節するための方法 Download PDF

Info

Publication number
JP2004523517A
JP2004523517A JP2002557211A JP2002557211A JP2004523517A JP 2004523517 A JP2004523517 A JP 2004523517A JP 2002557211 A JP2002557211 A JP 2002557211A JP 2002557211 A JP2002557211 A JP 2002557211A JP 2004523517 A JP2004523517 A JP 2004523517A
Authority
JP
Japan
Prior art keywords
combretastatin
pharmaceutical composition
agent
compound
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002557211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523517A5 (https=
Inventor
フランシス ワイ． リー，
ロナルド ペック，
デイビッド チャップリン，
ロナルド ペロ，
クラウス エバードセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2004523517A publication Critical patent/JP2004523517A/ja
Publication of JP2004523517A5 publication Critical patent/JP2004523517A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2002557211A 2000-12-22 2001-12-20 腫瘍増殖および転移を調節するための方法 Pending JP2004523517A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
PCT/US2001/050261 WO2002056692A1 (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008315096A Division JP2009102350A (ja) 2000-12-22 2008-12-10 腫瘍増殖および転移を調節するための方法

Publications (2)

Publication Number Publication Date
JP2004523517A true JP2004523517A (ja) 2004-08-05
JP2004523517A5 JP2004523517A5 (https=) 2005-12-22

Family

ID=22979500

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002557211A Pending JP2004523517A (ja) 2000-12-22 2001-12-20 腫瘍増殖および転移を調節するための方法
JP2008315096A Pending JP2009102350A (ja) 2000-12-22 2008-12-10 腫瘍増殖および転移を調節するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008315096A Pending JP2009102350A (ja) 2000-12-22 2008-12-10 腫瘍増殖および転移を調節するための方法

Country Status (5)

Country Link
EP (1) EP1351573A4 (https=)
JP (2) JP2004523517A (https=)
AU (1) AU2002246827B2 (https=)
CA (1) CA2432792C (https=)
WO (1) WO2002056692A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009102350A (ja) * 2000-12-22 2009-05-14 Bristol Myers Squibb Co 腫瘍増殖および転移を調節するための方法
JP2015091826A (ja) * 2007-10-10 2015-05-14 アンスティテュ、ナショナル、ド、ラ、サント、エ、ド、ラ、ルシェルシュ、メディカル（アンセルム）Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌ （Ｉｎｓｅｒｍ） 癌治療用の組合せ製品
JP2019524637A (ja) * 2016-08-26 2019-09-05 トンクワン アンハオ ファーマシューティカル カンパニー リミテッド 抗腫瘍薬物の効果を有する併用薬物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
HUP0302629A3 (en) 2000-10-27 2005-05-30 Aventis Pharma Sa Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
WO2004032947A1 (en) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009102350A (ja) * 2000-12-22 2009-05-14 Bristol Myers Squibb Co 腫瘍増殖および転移を調節するための方法
JP2015091826A (ja) * 2007-10-10 2015-05-14 アンスティテュ、ナショナル、ド、ラ、サント、エ、ド、ラ、ルシェルシュ、メディカル（アンセルム）Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌ （Ｉｎｓｅｒｍ） 癌治療用の組合せ製品
JP2019524637A (ja) * 2016-08-26 2019-09-05 トンクワン アンハオ ファーマシューティカル カンパニー リミテッド 抗腫瘍薬物の効果を有する併用薬物

Also Published As

Publication number Publication date
CA2432792C (en) 2012-04-03
AU2002246827B2 (en) 2008-02-21
WO2002056692A1 (en) 2002-07-25
CA2432792A1 (en) 2002-07-25
EP1351573A1 (en) 2003-10-15
JP2009102350A (ja) 2009-05-14
EP1351573A4 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
JP2009102350A (ja) 腫瘍増殖および転移を調節するための方法
US20090258937A1 (en) Methods for Modulating Tumor Growth and Metastasis
US20090209496A1 (en) Methods and compositions for enhancing the efficacy of rtk inhibitors
AU2006201008B2 (en) Combination chemotherapy
EP1173187B1 (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
AU2002246827A1 (en) Methods for modulating tumor growth and metastasis
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
JP2009536956A (ja) 抗癌治療法
CA3248166A1 (en) COMBINED USE OF AN ANTI-TROP-2 ANTIBODY DRUG CONJUGATE AND OTHER THERAPEUTIC AGENTS
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
US20180153931A1 (en) Antitumoral combination comprising cabazitaxel and cisplatin
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
AU2002216029A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
Endlicher et al. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study
HUP0103557A2 (hu) Antraciklinszármazék alkalmazása májtumor kezelésére
AU2004248968A1 (en) Compositions comprising ZD6126 together with 5-FU, CPT-11 or 5-FU and CPT-11 having vascular damaging activity for treating e.g. colorectal cancer
US20110110940A1 (en) Methods for Enhancing the Efficacy of Vascular Disrupting Agents
US20030130252A1 (en) Process for affecting neurologic progression
Di Costanzo et al. Cisplatin and Low-Dose Cytosine Arabinoside in Advanced Cancer
CN102245175A (zh) 含有ave8062 和多西紫杉醇的抗肿瘤组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100114